戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1 ences in clearance for IL-6 between CVVH and CVVHD did not translate into significant changes in circ
2                  Amino acid loss on CVVH and CVVHD was similar (12.50+/-1.29 g/day/1.73 m2 vs. 11.61+
3  and 29.0+/-.97 mL/min/1.73 m2) for CVVH and CVVHD, respectively.
4 as performed on six patients during CVVH and CVVHD.
5 d with an ultrafiltration rate of 2 L/hr and CVVHD with a dialysis outflow rate of 2 L/hr.
6 nted neutropenia while on valganciclovir and CVVHD; 60% of patients had significant thrombocytopenia.
7 CVVHD, 161 patients undergoing citrate-based CVVHD were screened for the presence of an elevated tota
8 ver failure patient undergoing citrate-based CVVHD with elevated serum total to ionized calcium ratio
9 o ionized calcium ratio during citrate-based CVVHD, 161 patients undergoing citrate-based CVVHD were
10 ing the mixed convection and diffusion-based CVVHD/F (2.7 +/- 1.9 mg/dL, N = 12; range, 0 to 6 mg/dL)
11 mg/kg/day during CVVH, and 245 mg/kg/day for CVVHD.
12 2 on CVVH and 7.59+/-2.79 mL/min/1.73 m2 for CVVHD (NS).
13 between therapies, 1.9+/-0.8 (SD) mL/min for CVVHD and 3.3+/-1.5 mL/min for CVVH, (p< .01).
14 s venovenous hemodialysis/hemodiafiltration (CVVHD/F).
15 ith continuous venovenous hemodiafiltration (CVVHD).
16  Use of continuous veno-venous hemodialysis (CVVHD) for RRT has been reported in three series of OLTX
17 ents on continuous veno-venous hemodialysis (CVVHD) is not known.
18 used for continuous venovenous hemodialysis (CVVHD) to minimize the risk of bleeding complications.
19 ort with continuous venovenous hemodialysis (CVVHD).
20 maintain nitrogen balance similar to that of CVVHD.
21 ve care unit from March 2018 to June 2019 on CVVHD.
22 /1.73 m2 to a positive 5.50 g/day/1.73 m2 on CVVHD.
23 oncentrations 0.60 ug/mL in most patients on CVVHD, similar to those reported with intravenous gancic
24 ugh concentrations 0.60 ug/mL in patients on CVVHD.
25   Clearance of AA is greater on CVVH than on CVVHD, but no significant difference in AA loss was pres
26 ations compared with a 23% increase while on CVVHD (p < .05).
27  vs. 50% in those patients who only received CVVHD postoperatively.
28                  However, patients receiving CVVHD both pre- and postoperatively had a 90-day mortali
29  highest being present in patients receiving CVVHD, which was started postoperatively.
30  after VAD placement, and all three required CVVHD until death.
31  ratio occurs commonly in patients requiring CVVHD using citrate-based regional anticoagulation.
32 ance using CVVH or diffusive clearance using CVVHD for the first 24 hrs, followed by the other modali
33 ma TNF-alpha concentrations as compared with CVVHD, while the type of transport mechanism used did no
34                        Patients treated with CVVHD had a 90-day mortality of 42% compared with 25% in